Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Alto Neuroscience, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Research and development
30.3
47
45.6
General and administrative
7.52
21.6
20.7
Operating expenses
37.8
68.6
66.4
Operating income
-37.8
-68.6
-66.4
Interest expense
1.37
1.38
2.47
Interest income
2.35
8.85
6.6
Other non-operating income
1.5
7.18
3.13
Income tax
0
0
0
Net income
-36.3
-61.4
-63.2
EBITDA
-37.4
-68.1
-65.7
EPS, basic
-9.73
-2.50
-2.19
EPS, diluted
-9.73
-2.50
-2.19
Shares, basic (weighted)
3.73
24.6
28.9
Shares, diluted (weighted)
3.73
24.6
28.9
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
82.5
168
176
Other current assets
0.11
0.03
1.23
Total current assets
85.4
169
178
Property, plant and equipment
1.11
2.67
1.87
Lease right-of-use assets
0
5.04
4.26
Total assets
86.6
178
185
Accounts payable
1.07
1.58
1.88
Accrued liabilities
4.54
8.43
8.86
Short-term debt
0
0
0.59
Total current liabilities
5.61
10
11.3
Long-term debt
9.86
10.3
16.2
Lease liabilities
0
4.52
3.82
Total liabilities
16.8
26.1
33.5
Total debt
9.86
10.3
16.8
Paid-in capital
5.37
290
353
Retained earnings
-77
-138
-202
Other comprehensive income
-0.08
-0.1
0.02
Shareholders' equity
-71.7
151
151
Total equity
-71.7
151
151
Total liabilities and equity
86.6
178
185
Shares outstanding
3.83
27
31.9
Cash flow statement
FY2024
FY2024
FY2025
Net income
-36.3
-61.4
-63.2
Depreciation and amortization
0.37
0.5
0.66
Stock-based compensation
2.89
7.63
8.11
Change in payables
-0.63
0.52
0.22
Cash from operations
-33.4
-47.4
-51.8
Capital expenditures
-0.47
-2.08
-0.02
Cash from investing
-0.47
-2.08
-0.02
Debt repaid
0
-10.2
Stock issued
0.18
0.19
0.7
Cash from financing
68.1
136
60.1
Exchange rate effect
-0.01
-0.01
-0.03
Net change in cash
34.2
86.2
8.26
Free cash flow
-33.9
-49.5
-51.8
Interest paid
0.91
1
1.66
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $26.49 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-38.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-33.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-0.2%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
4.0%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
17.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
14.9x
Current assets / current liabilities.
Quick ratio
14.6x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
14.6x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.07x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
6.4%
Total debt / total assets.
Liabilities / assets
13.7%
Total liabilities / total assets.
Net debt
-$227.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.61
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.59
Cash from operations / diluted weighted shares.
Book value per share
$6.25
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
4.74x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.74x
Market cap / tangible book value, when positive.
FCF yield
-6.6%
Free cash flow / market cap.
Earnings yield
-8.1%
Net income / market cap (the inverse of P/E).
Was Alto Neuroscience, Inc. profitable in fiscal 2025?
No. It reported a net loss of $63.2M.
How much free cash flow did Alto Neuroscience, Inc. generate in fiscal 2025?
Cash from operations of $51.8M minus capital expenditures of $24.0K left free cash flow of -$51.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.